Comparative efficacy of brigatinib versus ceritinib and alectinib in patients with crizotinib-refractory anaplastic lymphoma kinase-positive non-small cell lung cancer.

CONCLUSION: In crizotinib-refractory ALK + NSCLC patients, relative efficacy estimates suggest brigatinib may have prolonged PFS and OS vs ceritinib and prolonged PFS vs alectinib.
PMID: 30286627 [PubMed - as supplied by publisher]

Source: Current Medical Research and Opinion - October 6, 2018 Category: Research Tags: Curr Med Res Opin Source Type: research